ArticleClinical epigenetics2026
Chromatinopathies: clinically overlapping disorders, revealing novel variants and their DNA methylation signatures.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic Strategies in Pediatric Care: Addressing Rare Diseases in Children.Children (Basel, Switzerland) · 2026Review
- Correction: Chromatinopathies: clinically overlapping disorders, revealing novel variants and their DNA methylation signatures.Clinical epigenetics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChromatinopathies represent a genetically and clinically heterogeneous group of neurodevelopmental disorders (NDDs) caused by pathogenic variants in genes regulating chromatin structure and function. The phenotypic overlap and genetic complexity of these conditions pose significant diagnostic challenges, often resulting in unresolved variants of uncertain significance (VUS).
resultsWe investigated a cohort of 400 routine diagnostic individuals with NDD using whole-exome sequencing and genome-wide DNA methylation profiling via the clinically validated EpiSign assay. Episignature classification was used to aid in variant interpretation and to define molecular subtypes of chromatinopathy. Seventeen percent of individuals (67/400) harbored variants in chromatinopathy-associated genes, including 55 novel variants. DNA methylation profiling was performed in 60 individuals with 62 variants in chromatin regulator genes. Of these, 26 individuals (43%) exhibited disorder-specific episignatures consistent with the associated clinical diagnosis. Importantly, methylation profiles supported the pathogenicity of several variants previously classified as VUS and demonstrated diagnostic concordance with known disease-associated genes including ANKRD11, SETD5, KMT2A, KDM5C, CHD8, and others.
conclusionOur study highlights the improved diagnostic yield and clinical utility of combining genomic and epigenomic profiling in patients with clinically and/or genetically suspected chromatinopathies. Integration of EpiSign analysis facilitated variant reclassification, delineated genotype-epigenotype-phenotype correlations, and expanded the episignature atlas for rare neurodevelopmental disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.